Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 3/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2661485 | 0.93 | MAPK1 (0.35) | PIK3CDMAPK1TP53POLBMAPT | |
| SCHEMBL2661561 | 0.89 | CDK4 (0.37) | PIK3CDMAPK1POLBCYP3A4DPP4 | |
| SCHEMBL2661381 | 0.87 | CDK4 (0.39) | MAPK1POLBDPP4ACVR1 | |
| SCHEMBL2661001 | 0.85 | MAPK1 (0.38) | MAPK1MAPTCYP3A4DPP4PDE4A | |
| SCHEMBL2669596 | 0.84 | PDE4A (0.42) | MAPK1TP53POLBMAPTDPP4 | |
| SCHEMBL4919174 | 0.84 | NPY1R (0.40) | MAPK1TP53POLBMAPTALK | |
| SCHEMBL2669504 | 0.82 | GABRG2 (0.41) | POLBMAPTDPP4PIK3CA | |
| SCHEMBL2661260 | 0.82 | PIK3CA (0.36) | PIK3CDTP53POLBTHRBPIK3CA | |
| SCHEMBL2661337 | 0.82 | PDE4A (0.42) | MAPK1TP53POLBMAPTCYP3A4 | |
| SCHEMBL4920996 | 0.82 | MAPK1 (0.37) | PIK3CDMAPK1TP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778849-A | Fused quinoline derivatives useful as gaba modulators | ASTRAZENECA AB | 2010-07-14 | — | — | CN | claimed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | claimed |
| CN-101778849-A | Fused quinoline derivatives useful as gaba modulators | ASTRAZENECA AB | 2010-07-14 | — | — | CN | disclosed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | PIK3CD 3863/4885MAPK1 3191/4885TP53 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.